Last reviewed · How we verify
IBUTAMOREN
Ibutamoren, also known as MK-677, is a small molecule compound originally developed by Merck & Co. and currently owned by a subsidiary of Eli Lilly and Company. It is a growth hormone secretagogue, which means it stimulates the production of growth hormone in the body. However, its exact target and mechanism of action are not well understood. Ibutamoren has been studied for its potential to treat various conditions, including muscle wasting and osteoporosis, but it is not FDA-approved for any indication. Its commercial status and safety considerations are not well established.
At a glance
| Generic name | IBUTAMOREN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency (PHASE3)
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease (PHASE2)
- Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects (PHASE2)
- Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients (NA)
- Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032) (PHASE2)
- Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) (PHASE2)
- Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia (PHASE2)
- Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBUTAMOREN CI brief — competitive landscape report
- IBUTAMOREN updates RSS · CI watch RSS